Tempest Releases New Data Demonstrating Superiority of TPST-

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

New data package reveals improvements in multiple categories for TPST-1120 combined with atezolizumab + bevacizumab versus standard of care atezol...

Related Keywords

United States , California , Brisbane , Queensland , Australia , Roche Imbrave , Roche , Sylvia Wheeler , Stephen Brady , Aljanae Reynolds , Office For Health Improvement Disparities , Securities Exchange , World Health Organization , Tempest Therapeutics Inc , Exchange Commission On , Nasdaq , Randomized Clinical , East Asia , Securities Exchange Act , Securities Act , Tempest Therapeutics , Exchange Commission , Tempest Therapeutic , Clinical Oncology , Liver Cancer , Reviews Disease , Health Improvement ,